T1	p 61 114	bestatin of acute nonlymphocytic leukemia in adults .
T2	p 419 463	adult acute nonlymphocytic leukemia ( ANLL )
T3	p 628 679	101 eligible cases ( bestatin : 48 , control : 53 )
T4	i 37 69	chemoimmunotherapy with bestatin
T5	i 121 154	immunomodulating agent , bestatin
T6	i 163 171	Ubenimex
T7	i 337 359	bestatin immunotherapy
T8	i 380 414	remission maintenance chemotherapy
T9	i 552 566	bestatin group
T10	i 608 623	control group .
T11	i 647 659	( bestatin :
T12	i 700 708	bestatin
T13	i 879 887	bestatin
T14	i 1008 1016	Bestatin
T15	i 1061 1074	immunotherapy
T16	o 267 291	immunological response .
T17	o 731 740	remission
T18	o 803 813	survival .
T19	o 826 851	prolongation of remission
T20	o 1114 1136	survival and remission
T21	o 1179 1193	side-effects .